BeStock  
Stocks › Biotechnology › CRVS

Corvus Pharmaceuticals CRVS

US equityMarket cap rank #3290Biotechnology
$9.67 −$0.34 (-3.40%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.67 0.00%
Open$9.84
Prev close$10.01
Day range$9.56 – $10.04
Volume927.5K
Market cap$815.69M
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-14.8x
CheapRich

Near the bottom of its 5-year range · 20th percentile, 5-year average -5.9x

Price / book4.3x
CheapRich

Around its usual level · 58th percentile, 5-year average 6.2x

#4227 of 5329 stocks by PB (1 = cheapest)

P/E over five years

-578x-351x-125x102xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$15.06
Price vs. fair value-35.8%Trading below the estimate
Star rating★★★★☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 4.31 – 6.23 58% (pricier than usual) #4227 of 5329 (1 = cheapest)
PE -14.78 -8.81 -5.92 20% (cheaper than usual) –
PS – – 0.00 – –

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on CRVS.

Sign in to join the discussion.

Scroll to Top